New blood biomarker reduces the risk of misdiagnosing Alzheimer’s disease.

The new blood tests for diagnosing Alzheimer’s disease are providing increasingly better opportunities for early diagnosis, but one challenge is that the markers being measured change long before symptoms develop. Research led by Lund University now shows that a previously unused blood biomarker, when combined with current blood markers, can significantly reduce the risk of people receiving misleading information about the disease.

“By combining blood biomarkers, we can better identify which individuals have Alzheimer’s disease and which have the disease at a stage advanced enough to cause symptoms,” say the researchers behind the study.

Read more at: Medicinska fakulteten (Swedish) or Faculty of Medicine, Lund University (English)

Read the paper in: Lancet Neurology

Niklas Mattsson-Carlgren, associate
professor at Lund University and
neurologist at Skåne University Hospital.
Photo: Tove Smeds.